Deceleration in the rate of keratinocyte cancers and precancerous lesions during programmed death-1 inhibition therapy for advanced melanoma, with recrudescence on discontinuation

Clin Exp Dermatol. 2022 Mar;47(3):582-584. doi: 10.1111/ced.14974. Epub 2021 Dec 28.

Authors

L Roche¹, B Moriarty¹, A Fabre², J Crowne³, A Lally¹

Affiliations

¹ Departments of Dermatology,, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.
² Histopathology, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.
³ Medical Oncology, St Vincent's Healthcare Group Strategic Skin Cancer Network, St Vincent's University Hospital, Dublin, Ireland.

PMID: 34633688
DOI: 10.1111/ced.14974

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Basal Cell / diagnosis
Carcinoma, Squamous Cell / diagnosis
Female
Humans
Keratinocytes / pathology
Melanoma / drug therapy*
Melanoma / pathology
Neoplasm Recurrence, Local
Precancerous Conditions / diagnosis*
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Skin Neoplasms / diagnosis*
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Withholding Treatment

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor
pembrolizumab